Literature DB >> 25313207

Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.

Seong Mi Moon1, Hye Yun Park1, Byeong-Ho Jeong1, Kyeongman Jeon1, Soo-Youn Lee2, Won-Jung Koh3.   

Abstract

We investigated the effects of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis. Serum itraconazole concentrations were significantly lower in patients who received itraconazole with rifampin (median, 0.1 μg/ml; P < 0.001) or rifabutin (median, 0.34 μg/ml; P < 0.001) than those receiving itraconazole alone (median, 5.92 μg/ml). Concomitant use of rifampin or rifabutin and itraconazole should be avoided in patients with chronic pulmonary aspergillosis and coexisting mycobacterial infections.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25313207      PMCID： PMC4291413          DOI： 10.1128/AAC.04075-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Itraconazole and anti-tuberculosis drugs.

Authors:  M Blomley; E L Teare; A de Belder; Y Thway; M Weston
Journal:  Lancet       Date:  1990-11-17       Impact factor: 79.321

Review 3.  Chronic pulmonary aspergillosis: an update on diagnosis and treatment.

Authors:  Cendrine Godet; Bruno Philippe; François Laurent; Jacques Cadranel
Journal:  Respiration       Date:  2014-06-17       Impact factor: 3.580

4.  Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease.

Authors:  Yoshihiro Kobashi; Minoru Fukuda; Kouichiro Yoshida; Naoyuki Miyashita; Yoshihito Niki; Mikio Oka
Journal:  Respirology       Date:  2006-11       Impact factor: 6.424

5.  Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole.

Authors:  J Drayton; G Dickinson; M G Rinaldi
Journal:  Clin Infect Dis       Date:  1994-02       Impact factor: 9.079

6.  Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis.

Authors:  I Hafeez; M F Muers; S A Murphy; E G Evans; R C Barton; P McWhinney
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

7.  Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis.

Authors:  H Kunst; M Wickremasinghe; A Wells; R Wilson
Journal:  Eur Respir J       Date:  2006-04-12       Impact factor: 16.671

8.  Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients.

Authors:  S Jaruratanasirikul; S Sriwiriyajan
Journal:  Eur J Clin Pharmacol       Date:  1998-04       Impact factor: 2.953

9.  Effect of rifampicin on the pharmacokinetics of fluconazole in patients with AIDS.

Authors:  Duangchit Panomvana Na Ayudhya; Nawarat Thanompuangseree; Somsit Tansuphaswadikul
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations.

Authors:  R M Tucker; D W Denning; L H Hanson; M G Rinaldi; J R Graybill; P K Sharkey; D Pappagianis; D A Stevens
Journal:  Clin Infect Dis       Date:  1992-01       Impact factor: 9.079
View more
  4 in total

Review 1.  Chronic Pulmonary Aspergillosis Following Nontuberculous Mycobacterial Infections: An Emerging Disease.

Authors:  Pakpoom Phoompoung; Methee Chayakulkeeree
Journal:  J Fungi (Basel)       Date:  2020-12-08

2.  Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease.

Authors:  Byung Woo Jhun; Woo Jin Jung; Na Young Hwang; Hye Yun Park; Kyeongman Jeon; Eun-Suk Kang; Won-Jung Koh
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

Review 3.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07

4.  A Case of Oral Histoplasmosis Concomitant with Pulmonary Tuberculosis.

Authors:  Silas Antonio Juvencio de Freitas Filho; Natália Galvão Garcia; Mário César de Souza; Denise Tostes Oliveira
Journal:  Case Rep Dent       Date:  2019-11-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.